Replies to post #31692 on Pluristem Therapeutics Inc (PSTI)

[hopester]

This kind of bio-tech's sh/px is not measured on a px/ern multiples basis. R/D companies never do. They sell on prospects, perceived need and demand.
So at least for the 1st 1 or 2 years after approvals and ramped up commercialization their multiple would be about:

ONE GAZILLION TO ONE

[Mikems]

It could go up to 10 or 11 at best.

[skitahoe]

If your speaking of a P/E ratio, I think the general range is 10 to 30 times earnings, based on the potential to grow. I believe that growth could be great as both new applications are found for existing drugs, and new drugs are approved, so I'd put it closer to 30 times earnings.

Gary